Prospective Study of Head and Neck Cancer Radiation Treatment With or Without Amifostine

• Status: Suspended
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the incidence of stomatitis when treating with amifostine before radiation treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Pharmaceutical Industries Limited
• Treatments: Amifostine

Criteria

Inclusion Criteria:

1. 18-70 years old, male or female

2. Primary treatment of phase I-IVA head and neck cancer patients, identified by histological and pathological diagnosis

3. Postoperative patients should receive radiation treatment in 12 weeks

4. ECOG <2

5. Expected lifetime ≥6months

6. No severe complications (hypertension, CHD, diabetes and psychiatric history, etc.)

7. Not involved in other clinical trials

8. Sign ICF

Exclusion Criteria:

1. ECOG >2

2. Suffered other cancers in the past 5 years

3. Received amifostine treatment in the past 4 weeks

4. Unable to complete treatment or sign ICF because of medical or physical reasons